Ayurcann Receives Standard Processing License From Health Canada

Ayurcann Inc. News Release
FOR IMMEDIATE RELEASE, January 31, 2020

Pickering, Ontario, January 31, 2020– Ayurcann Inc. operating as XTRX Solutions (“XTRX” and/or “Company”), announced today that it has received its Standard Processing License (“Processing License”). According to Health Canada’s new Cannabis Act regulations, the Processing License is required for any facility that is processing more than the equivalent of 600 kg of dried flowers per year. This license means that, in addition to XTRX’s Research & Development License, it can now extract, manufacture, synthesize and test next-generation cannabis products.

Igal Sudman, Co-Founder and CEO, stated, “This is a milestone for our Company and is welcome news for our Pickering facility. Receiving the Processing License allows the Company the ability to carry out research and development on cannabis, and to extract cannabinoids and manufacture next-generation cannabis products, all of which are important steps forward for XTRX. This Processing License will allow us to develop and offer a wide-range of high-quality cannabis derivative products, launch and advance XTRX brands, and to serve recreational and medicinal consumers in Ontario and throughout Canada.”

About XTRX Solutions.

XTRX Solutions mission is to be the leading provider of customized post-harvest outsourcing solutions to licensed cannabis producers. We offer end-to-end full outsource solutions to licensed producers which include Extraction & Refinement, Formulation & Packaging, Fulfillment & Distribution. A customer LP is able to focus on their genetics, cultivation and harvesting operations and outsource all of the rest to XTRX Solutions. For more information please visit www.xtrx.ca.

For further information please contact:
Natalie Dolphin
Director of Business Development
XTRX Solutions
T: (905) 492-3322 x 311
E: natalie@xtrx.ca

Forward-Looking Statements

Information set forth in this news release may involve forward-looking statements under applicable securities laws. The forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document and the Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities legislation. Although Management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release. Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the future plans, objectives or goals, including words to the effect that the company or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.

Subscribe to our newsletter to stay up-to-date with Ayurcann.